anti-C3/VEGF receptor gene therapy (Chengdu Kanghong Pharmaceuticals)

N/A

Report date: 2025/06/11 10:54:09

Base Information

Drug Nameanti-C3/VEGF receptor gene therapy (Chengdu Kanghong Pharmaceuticals)
Drug Alias NameAAV.CB.anti-C3-anti-VEGF
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionComplement C3 inhibitorsVascular endothelial growth factor modulators
TargetsComplement C3Vascular endothelial growth factor
Therapy Area/IndicationsGeographic Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChengdu Kanghong Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Kanghong Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsGeographic Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A